Interleukin-4 - Ono
Latest Information Update: 24 Oct 2021
At a glance
- Originator Ono Pharmaceutical
- Class Interleukins
- Mechanism of Action B cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Apr 2013 Discontinued for Cancer in Japan (unspecified route)
- 14 Sep 1995 No-Development-Reported for Cancer in Japan (Unknown route)